On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Sarepta's boardroom intrigue clouds a promising drug's future

After Sarepta Therapeutics' former head scientist blamed his swift ouster on "serious disagreements" with CEO Chris Garabedian, the company has moved to limit its chief executive's power, according to a report, especially when it comes to meetings with the FDA over the biotech's much-scrutinized lead drug.

UPDATED: Amgen axing up to 2,900 staffers, shuttering sites in major restructuring

Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that it plans to trim up to 15% of the company's workforce, shutting down facilities in Colorado and Washington state as it slashes up to 2,900 staffers.

PCI ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE PENN PHARMA

PCI ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE PENN PHARMA PCI's Expands Service Offering with Acquisition of Penn Pharma Philadelphia, PA – July 28, 2014 - Packaging Coordinators, Inc....

Quark's RNAi treatment misses the mark in a Phase II kidney trial

Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis worth up to $680 million.

Quark Pharmaceuticals Reports Favorable Results From Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002

Jul 28, 2014 -- Data on siRNA for the Prophylaxis of Delayed Graft Function in Deceased Donor Kidney Transplant Patients Presented at World Transplant Congress Proof of Concept for First-in-Class...

Neurotrope Initiates Phase 2a Study of Bryostatin for the Treatment of Alzheimer's Disease - Doses First Patients

PLANTATION, Fla., July 29, 2014 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP) announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with...

Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc.

PARIS, Jul 29, 2014 (BUSINESS WIRE) -- Regulatory News: Cellectis FR:ALCLS +4.00% (alternext:ALCLS.PA), a leader in the development of adoptive immunotherapies based on engineered allogeneic CART...

Galectin shares crater on NASH analysis; Cellectis sells subsidiary, concentrates on CAR-T;

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech @JohnCFierce: Resurgent Merck to accelerate R&D spending in H2, hunt new...

Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma

- First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel...